A Study to Assess the Effect of Doctor's Biome Medical Food in Individuals With Clostridium Difficile Infection

NCT ID: NCT06367504

Last Updated: 2024-06-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-15

Study Completion Date

2024-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, double-blind, placebo-controlled, pilot clinical study to assess the effect of Doctor's Biome Medical Food (DBMF) in individuals with Clostridium difficile infection (CDI)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Clostridium Difficile Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, parallel group, double-blind, placebo-controlled trial
Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Doctor's Biome Medical Food (DBMF)

Once a day daily 30 minutes before lunch

Group Type ACTIVE_COMPARATOR

DBMF

Intervention Type DIETARY_SUPPLEMENT

Once a day daily 30 minutes before lunch

Placebo

Once a day daily 30 minutes before lunch

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Once a day daily 30 minutes before lunch

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DBMF

Once a day daily 30 minutes before lunch

Intervention Type DIETARY_SUPPLEMENT

Placebo

Once a day daily 30 minutes before lunch

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females of 30 - 75 years of age.
2. A qualifying episode of CDI as defined by:

1. ≥ 3 abnormal stools as assessed by BSFS score of 6 \& 7 in the last 24 hours.
2. A positive C. difficile stool toxin assay as assessed by C. difficile toxins A \& B - CARD\*.
3. The requirement of CDI Standard of Care (SOC) antibiotic therapy (as per PI's discretion). 3) Individuals willing to give voluntary, written informed consent to participate in the study.

4\) Individuals without/with antibiotic-associated diarrhea (indicated by use of antibiotics any time in last one week) will also be considered for the testing of C. difficile toxins

Exclusion Criteria

1. History or presence of terminal/end-stage renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic or neurologic disorders (which might confound the interpretation of the study results, or put the individual at undue risk).
2. History of peptic ulcer.
3. History of abdominal surgery within the previous 3 months.
4. Presence of colostomy, gastric-tube, or naso-gastric-tube.
5. Individuals requiring any gastrointestinal surgery planned during the next 3 months.
6. HIV, AIDS, primarily immunodeficiency, cancer
7. Individuals with a very recent (\< 1 year) solid organ or bone marrow transplant.
8. Individuals requiring blood transfusion or renal dialysis planned during the next 3 months.
9. Unwilling to abstain using kombucha, sauerkraut, pickles and kimchi
10. Individuals with the following food intolerance - gluten, lactose, and/or histamine.
11. Heavy alcohol drinkers are defined as follows: For men, consuming more than 4 drinks on any day or more than 14 drinks/week. For women, consuming more than 3 drinks on any day or more than 7 drinks/week.
12. Smokers.
13. Females who are pregnant/planning to be pregnant/lactating or taking any oral contraceptives.
14. Individuals who have participated in another clinical study(ies) with an investigational product within 90 days before screening, or who plan to participate in another study during the study period.
15. Use of any supplements (may include probiotics, post-biotics, herbal supplements, synbiotics, enzyme supplementation the last 30 days.
Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vedic Lifesciences Pvt. Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AIMS Hospital

Dombivali, Maharashtra, India

Site Status

Stress Test Clinic

Mumbai, Maharashtra, India

Site Status

Nobel Hospital

Pune, Maharashtra, India

Site Status

Gleneagles Hospital

Hyderabad, Telangana, India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dr. Shalini Srivastava,, MBBS, MD

Role: CONTACT

9920789140

Dr Shubhangi Mote, BAMS

Role: CONTACT

8655448527

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dr Sandeep Kardian, MBBS MD

Role: primary

870364574

Dr Ramesh Dargad, MBBS MS

Role: primary

9820152828

Dr Pramod Katare, MBBS MD

Role: primary

8830793201

Dr G S Sameer Kumar, MBBS MD

Role: primary

8860031692

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DB/230904/DBMF/CDI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Probiotics in Dementia
NCT03847714 COMPLETED NA